Emergent BioSolutions Seattle (formerly Trubion Pharmaceuticals) is a global biopharmaceutical company focused on the manufacture, development and commercialization of vaccines and antibody therapeutics. Trubion’s clinical and preclinical stage programs, as well as its novel technology platforms, will expand Emergent’s product development pipeline into the key disease indications of oncology and autoimmunity, and significantly broaden its antibody-based capabilities. The Seattle, Washington facility is now known as Emergent Product Development Seattle and will continue to focus on developing unique therapeutic products.

On August 12, 2010, Emergent BioSolutions announced an agreement to acquire Trubion Pharmaceuticals for upfront consideration of $96.8 million of value and up to $38.7 million of success-based milestones, resulting in a total consideration of up to $135.5 million.